{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:51:58Z","timestamp":1776408718979,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Japanese Society for the Promotion of Science (JSPS) KAKENHI","award":["JP24K11565"],"award-info":[{"award-number":["JP24K11565"]}]},{"name":"Japanese Society for the Promotion of Science (JSPS) KAKENHI","award":["JP23H02939"],"award-info":[{"award-number":["JP23H02939"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06896-3","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:27:46Z","timestamp":1771824466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment of relapsed FLT3-mutated donor cell-derived MDS\/AML with FLT3 inhibitor gilteritinib"],"prefix":"10.1007","volume":"105","author":[{"given":"Mana","family":"Kawano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0511-2583","authenticated-orcid":false,"given":"Hiroyoshi","family":"Kunimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodai","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayoko","family":"Shirafuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"2","key":"6896_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/bjh.12847","volume":"166","author":"AC Dietz","year":"2014","unstructured":"Dietz AC, DeFor TE, Brunstein CG, Wagner JE Jr (2014) Donor-derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response. Br J Haematol 166(2):209\u2013212. https:\/\/doi.org\/10.1111\/bjh.12847","journal-title":"Br J Haematol"},{"issue":"2","key":"6896_CR2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41375-018-0218-6","volume":"33","author":"N Engel","year":"2019","unstructured":"Engel N, Rovo A, Badoglio M, Labopin M, Basak GW, Beguin Y et al (2019) European experience and risk factor analysis of donor cell-derived leukaemias\/MDS following haematopoietic cell transplantation. Leukemia 33(2):508\u2013517. https:\/\/doi.org\/10.1038\/s41375-018-0218-6","journal-title":"Leukemia"},{"issue":"2","key":"6896_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1073\/pnas.91.2.459","volume":"91","author":"D Small","year":"1994","unstructured":"Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P et al (1994) STK-1, the human homolog of Flk-2\/Flt-3, selectively expressed in CD34+\u2009 human bone marrow cells and is involved in the proliferation of early progenitor\/stem cells. Proc Natl Acad Sci USA 91(2):459\u2013463. https:\/\/doi.org\/10.1073\/pnas.91.2.459","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"6896_CR4","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/leu.2014.55","volume":"28","author":"R Kihara","year":"2014","unstructured":"Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K et al (2014) Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 28(8):1586\u20131595. https:\/\/doi.org\/10.1038\/leu.2014.55","journal-title":"Leukemia"},{"issue":"18","key":"6896_CR5","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S et al (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML. N Engl J Med 381(18):1728\u20131740. https:\/\/doi.org\/10.1056\/NEJMoa1902688","journal-title":"N Engl J Med"},{"issue":"6","key":"6896_CR6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.leukres.2009.10.001","volume":"34","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O\u2019Brien S, Koller C et al (2010) Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res 34(6):752\u2013756. https:\/\/doi.org\/10.1016\/j.leukres.2009.10.001","journal-title":"Leuk Res"},{"issue":"7","key":"6896_CR7","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N et al (2019) Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 20(7):984\u2013997. https:\/\/doi.org\/10.1016\/S1470-2045(19)30150-0","journal-title":"Lancet Oncol"},{"issue":"9","key":"6896_CR8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J et al (2020) Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic Haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol 21(9):1201\u20131212. https:\/\/doi.org\/10.1016\/S1470-2045(20)30455-1","journal-title":"Lancet Oncol"},{"issue":"26","key":"6896_CR9","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz FV, Finke J, Stelljes M, R\u00f6llig C et al (2020) Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol 38(26):2993\u20133002. https:\/\/doi.org\/10.1200\/JCO.19.03345","journal-title":"J Clin Oncol"},{"issue":"2","key":"6896_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bbmt.2020.09.036","volume":"27","author":"S Ganguly","year":"2021","unstructured":"Ganguly S, Cortes JE, Kr\u00e4mer A, Levis MJ, Martinelli G, Perl AE et al (2021) Clinical outcomes in patients with FLT3-ITD-mutated relapsed\/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after Quizartinib or salvage chemotherapy in the QuANTUM-R trial. Transpl Cell Ther 27(2):153\u2013162. https:\/\/doi.org\/10.1016\/j.bbmt.2020.09.036","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"6896_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jtct.2022.12.006","volume":"29","author":"AE Perl","year":"2023","unstructured":"Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E et al (2023) Outcomes in patients with FLT3-mutated relapsed\/refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy. Transpl Cell Ther 29(4):265. https:\/\/doi.org\/10.1016\/j.jtct.2022.12.006","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"6896_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1182\/bloodadvances.2022008991","volume":"7","author":"T Terao","year":"2023","unstructured":"Terao T, Matsuoka K, Ueda H, Matsumura A, Matsubara C, Kondo K et al (2023) Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R\/R FLT3 mut AML. Blood Adv 7(5):681\u2013686. https:\/\/doi.org\/10.1182\/bloodadvances.2022008991","journal-title":"Blood Adv"},{"issue":"1","key":"6896_CR13","doi-asserted-by":"publisher","first-page":"2220518","DOI":"10.1080\/16078454.2023.2220518","volume":"28","author":"N Hirose","year":"2023","unstructured":"Hirose N, Tachibana T, Izumi A, Sato S, Tadera N, Tamai Y et al (2023) Bridging to transplant and post-transplant maintenance therapy with FLT3 inhibitors in patients with relapsed or refractory FLT3 mutated acute myeloid leukemia. Hematology 28(1):2220518. https:\/\/doi.org\/10.1080\/16078454.2023.2220518","journal-title":"Hematology"},{"issue":"10","key":"6896_CR14","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/ng.2731","volume":"45","author":"A Kon","year":"2013","unstructured":"Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y et al (2013) Recurrent mutations in multiple components of the cohesion complex in myeloid neoplasms. Nat Genet 45(10):1232\u20131237. https:\/\/doi.org\/10.1038\/ng.2731","journal-title":"Nat Genet"},{"issue":"22","key":"6896_CR15","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al (2013) Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122(22):3616\u20133627. https:\/\/doi.org\/10.1182\/blood-2013-08-518886","journal-title":"Blood"},{"issue":"7","key":"6896_CR16","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/s41409-021-01214-z","volume":"56","author":"L Williams","year":"2021","unstructured":"Williams L, Doucette K, Karp JE, Lai C (2021) Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome. Bone Marrow Transpl 56(7):1535\u20131549. https:\/\/doi.org\/10.1038\/s41409-021-01214-z","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"6896_CR17","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1038\/leu.2015.67","volume":"29","author":"CN Hahn","year":"2015","unstructured":"Hahn CN, Ross DM, Feng J, Beligaswatte A, Hiwase DK, Parker WT et al (2015) A Tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone. Leukemia 29(10):2101\u20132104. https:\/\/doi.org\/10.1038\/leu.2015.67","journal-title":"Leukemia"},{"issue":"7","key":"6896_CR18","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2017.104","volume":"31","author":"S Herold","year":"2017","unstructured":"Herold S, Kuhn M, Bonin MV, Stange T, Platzbecker U, Radke J et al (2017) Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient. Leukemia 31(7):1637\u20131640. https:\/\/doi.org\/10.1038\/leu.2017.104","journal-title":"Leukemia"},{"issue":"9","key":"6896_CR19","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/bmt.2011.256","volume":"47","author":"K Chonabayashi","year":"2012","unstructured":"Chonabayashi K, Kondo T, Yamamoto K, Tanaka Y, Nagai Y, Hishizawa M et al (2012) Successful use of second cord blood transplantation to achieve long-term remission in cord blood donor cell-derived AML harboring a FLT3-ITD and an NPM1 mutation. Bone Marrow Transpl 47(9):1252\u20131253. https:\/\/doi.org\/10.1038\/bmt.2011.256","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"6896_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","volume":"127","author":"D Grimwade","year":"2016","unstructured":"Grimwade D, Ivey A, Huntly BJP (2016) Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood 127(1):29\u201341. https:\/\/doi.org\/10.1182\/blood-2015-07-604496","journal-title":"Blood"},{"issue":"12","key":"6896_CR21","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1038\/s41375-020-0795-z","volume":"34","author":"S Husby","year":"2020","unstructured":"Husby S, Favero F, Neilsen C, S\u00f8rensen BS, B\u00e6ch J, Grell K et al (2020) Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a National population-based cohort study. Leukemia 34(12):3256\u20133268","journal-title":"Leukemia"},{"issue":"6","key":"6896_CR22","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00277-022-04806-x","volume":"101","author":"D Gramegna","year":"2022","unstructured":"Gramegna D, Bertoli D, Cattaneo C, Almici C, Re A, Belotti A et al (2022) The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation. Ann Hematol 101(6):1227\u20131237","journal-title":"Ann Hematol"},{"issue":"21","key":"6896_CR23","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1182\/bloodadvances.2021004668","volume":"5","author":"A Stengel","year":"2021","unstructured":"Stengel A, Baer C, Walter W, Meggendorfer M, Kern W, Haferlach T et al (2021) Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. Blood Adv 5(21):4426\u20134434","journal-title":"Blood Adv"},{"issue":"10","key":"6896_CR24","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1002\/ajh.70014","volume":"100","author":"ME Selvan","year":"2025","unstructured":"Selvan ME, Kuan PF, Yang X, Mascarenhas J, Klein RJ, Luft BJ et al (2025) Distinct characteristics of lymphoid and myeloid clonal hematopoiesis in world trade center first responders. Am J Hematol 100(10):1873\u20131877","journal-title":"Am J Hematol"},{"issue":"11","key":"6896_CR25","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1084\/jem.20151323","volume":"212","author":"J Mullenders","year":"2015","unstructured":"Mullenders J, Aranda-Orgilles B, Lhoumaud P, Keller M, Pae J, Wang K et al (2015) Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. J Exp Med 212(11):1833\u20131850","journal-title":"J Exp Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06896-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06896-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06896-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:57Z","timestamp":1776405597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06896-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6896"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06896-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The participant has consented to the submission of the case report to the journal and written informed consent for publication was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"This work was conducted in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}}],"article-number":"134"}}